Merck & Co., Inc. (LON: MRK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 196.52B |
| Revenue (ttm) | 47.13B |
| Net Income (ttm) | 9.06B |
| Shares Out | n/a |
| EPS (ttm) | 3.57 |
| PE Ratio | 21.68 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,000 |
| Average Volume | 170,652 |
| Open | 54.45 |
| Previous Close | 54.00 |
| Day's Range | 54.45 - 54.70 |
| 52-Week Range | 48.00 - 80.00 |
| Beta | 0.71 |
| RSI | 74.10 |
| Earnings Date | Feb 4, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial numbers in USD Financial StatementsNews
Mike Ashley’s Frasers buys £3m stake in Marks Electrical
In a stock market filing, Marks revealed that Frasers has bought 6.73 million shares in the business.
Three Quick Facts: AstraZeneca, Marks Electrical, BAE Systems
Buoyant demand sustains revenue growth at AstraZeneca, solid revenue growth at Marks Electrical, BAE Systems on track following upgrades